Topics

High-grade gliomas | Treatment | Targeted therapy | Overview

Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Overview

Stitzlein LM, Adams JT, Stitzlein EN, Dudley RW, Chandra J.
Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
J Exp Clin Cancer Res. 2024 Jan 5;43(1):12. doi: 10.1186/s13046-023-02923-7. PMID: 38183103. Review. ˍ

Koizumi S, Oishi T, Iwaizumi M, Kurozumi K.
Genomic medicine advances for brain tumors.
Int J Clin Oncol. 2024 May 10. doi: 10.1007/s10147-024-02522-2. PMID: 38727852. Review˰ ˍ

Hsueh B, Steuart SJ, Odukoya AO, Prager BC, Kim YJ, Hill CM, Choi BD, Dunn GP.
Immunotherapy and targeted therapy for high grade gliomas: current and future directions.
J Neurooncol. 2025 Dec 9;176(1):112. doi: 10.1007/s11060-025-05315-3. PMID: 41366148. Review˰ ˍ

Wang D, Zhang J, Liu G, Bu C, Wei S, Li M, Lv G, Sheng Z, Mei J, Yan Z, Gao Y, Zhao R, Shi Y, Wang M, Bu X.
Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis.
Neurooncol Adv. 2026 Feb 16;8(1):vdag040. doi: 10.1093/noajnl/vdag040. PMID: 41778154. Observational study. ˍ